These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 15290121)

  • 21. Radioimmunoscintigraphy and biodistribution of technetium-99m-labeled monoclonal antibody U36 in patients with head and neck cancer.
    de Bree R; Roos JC; Quak JJ; den Hollander W; Snow GB; van Dongen GA
    Clin Cancer Res; 1995 Jun; 1(6):591-8. PubMed ID: 9816020
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of the biodistribution and the efficacy of monoclonal antibody 323/A3 labeled with either 131I or 186Re in human ovarian cancer xenografts.
    Kievit E; van Gog FB; Schlüper HM; van Dongen GA; Pinedo HM; Boven E
    Int J Radiat Oncol Biol Phys; 1997 Jul; 38(4):813-23. PubMed ID: 9240651
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Superior localisation and imaging of radiolabelled monoclonal antibody E48 F(ab')2 fragment in xenografts of human squamous cell carcinoma of the head and neck and of the vulva as compared to monoclonal antibody E48 IgG.
    Gerretsen M; Quak JJ; Suh JS; van Walsum M; Meijer CJ; Snow GB; van Dongen GA
    Br J Cancer; 1991 Jan; 63(1):37-44. PubMed ID: 1989663
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting of aluminum (III) phthalocyanine tetrasulfonate by use of internalizing monoclonal antibodies: improved efficacy in photodynamic therapy.
    Vrouenraets MB; Visser GW; Stigter M; Oppelaar H; Snow GB; van Dongen GA
    Cancer Res; 2001 Mar; 61(5):1970-5. PubMed ID: 11280754
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting of a hydrophilic photosensitizer by use of internalizing monoclonal antibodies: A new possibility for use in photodynamic therapy.
    Vrouenraets MB; Visser GW; Loup C; Meunier B; Stigter M; Oppelaar H; Stewart FA; Snow GB; van Dongen GA
    Int J Cancer; 2000 Oct; 88(1):108-14. PubMed ID: 10962447
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A novel CD44v6 targeting antibody fragment with improved tumor-to-blood ratio.
    Sandström K; Haylock AK; Spiegelberg D; Qvarnström F; Wester K; Nestor M
    Int J Oncol; 2012 May; 40(5):1525-32. PubMed ID: 22307465
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immuno-PET of human colon xenograft- bearing BALB/c nude mice using 124I-CDR-grafted humanized A33 monoclonal antibody.
    Lee FT; Hall C; Rigopoulos A; Zweit J; Pathmaraj K; O'Keefe GJ; Smyth FE; Welt S; Old LJ; Scott AM
    J Nucl Med; 2001 May; 42(5):764-9. PubMed ID: 11337573
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SPECT imaging of neuropilin receptor type-1 expression with 131I-labeled monoclonal antibody.
    Dou X; Yan J; Zhang Y; Liu P; Jiang Y; Lv S; Zeng F; Chen X; Wang S; Zhang H; Wu H; Zhang H; Ouyang L; Su X
    Int J Oncol; 2016 Sep; 49(3):961-70. PubMed ID: 27315007
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics, biodistribution, and dosimetry of specific and control radiolabeled monoclonal antibodies in patients with primary head and neck squamous cell carcinoma.
    Maraveyas A; Stafford N; Rowlinson-Busza G; Stewart JS; Epenetos AA
    Cancer Res; 1995 Mar; 55(5):1060-9. PubMed ID: 7866989
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of an internalizing monoclonal antibody labeled using N-succinimidyl 3-[131I]iodo-4-phosphonomethylbenzoate ([131I]SIPMB), a negatively charged substituent bearing acylation agent.
    Shankar S; Vaidyanathan G; Affleck DJ; Peixoto K; Bigner DD; Zalutsky MR
    Nucl Med Biol; 2004 Oct; 31(7):909-19. PubMed ID: 15464393
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biodistribution of radiolabeled monoclonal antibody E48 IgG and F(ab')2 in patients with head and neck cancer.
    de Bree R; Roos JC; Quak JJ; den Hollander W; Wilhelm AJ; van Lingen A; Snow GB; Dongen GA
    Clin Cancer Res; 1995 Mar; 1(3):277-86. PubMed ID: 9815983
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PET imaging of prostate cancer xenografts with a highly specific antibody against the prostate-specific membrane antigen.
    Elsässer-Beile U; Reischl G; Wiehr S; Bühler P; Wolf P; Alt K; Shively J; Judenhofer MS; Machulla HJ; Pichler BJ
    J Nucl Med; 2009 Apr; 50(4):606-11. PubMed ID: 19289418
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Localization of 131I-labelled monoclonal antibody ERIC1 in a subcutaneous xenograft model of neuroblastoma in SCID mice.
    Otto C; Jensen M; Dietlein M; Fischer T; Schmidt M; Tawadros S; Börner SM; Weber SA; Spitz R; Bloch W; Berthold F; Schicha H; Schomäcker K
    Nucl Med Commun; 2006 Feb; 27(2):171-8. PubMed ID: 16404231
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I therapy study of 186Re-labeled chimeric monoclonal antibody U36 in patients with squamous cell carcinoma of the head and neck.
    Colnot DR; Quak JJ; Roos JC; van Lingen A; Wilhelm AJ; van Kamp GJ; Huijgens PC; Snow GB; van Dongen GA
    J Nucl Med; 2000 Dec; 41(12):1999-2010. PubMed ID: 11138685
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biodistribution and kinetics of (131)I-labelled anti-CD20 MAB IDEC-C2B8 (rituximab) in relapsed non-Hodgkin's lymphoma.
    Scheidhauer K; Wolf I; Baumgartl HJ; Von Schilling C; Schmidt B; Reidel G; Peschel C; Schwaiger M
    Eur J Nucl Med Mol Imaging; 2002 Oct; 29(10):1276-82. PubMed ID: 12271407
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Advantage of a residualizing iodine radiolabel for radioimmunotherapy of xenografts of human non-small-cell carcinoma of the lung.
    Stein R; Goldenberg DM; Thorpe SR; Mattes MJ
    J Nucl Med; 1997 Mar; 38(3):391-5. PubMed ID: 9074526
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Monoclonal antibodies labeled with rhenium-186 using the MAG3 chelate: relationship between the number of chelated groups and biodistribution characteristics.
    van Gog FB; Visser GW; Klok R; van der Schors R; Snow GB; van Dongen GA
    J Nucl Med; 1996 Feb; 37(2):352-62. PubMed ID: 8667076
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preclinical therapy of breast cancer with a radioiodinated humanized anti-EGP-1 monoclonal antibody: advantage of a residualizing iodine radiolabel.
    Govindan SV; Stein R; Qu Z; Chen S; Andrews P; Ma H; Hansen HJ; Griffiths GL; Horak ID; Goldenberg DM
    Breast Cancer Res Treat; 2004 Mar; 84(2):173-82. PubMed ID: 14999147
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of meta-tetrahydroxyphenylchlorin-monoclonal antibody conjugates for photoimmunotherapy.
    Vrouenraets MB; Visser GW; Stewart FA; Stigter M; Oppelaar H; Postmus PE; Snow GB; van Dongen GA
    Cancer Res; 1999 Apr; 59(7):1505-13. PubMed ID: 10197621
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Advantage of a residualizing iodine radiolabel in the therapy of a colon cancer xenograft targeted with an anticarcinoembryonic antigen monoclonal antibody.
    Stein R; Govindan SV; Hayes M; Griffiths GL; Hansen HJ; Horak ID; Goldenberg DM
    Clin Cancer Res; 2005 Apr; 11(7):2727-34. PubMed ID: 15814655
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.